Takemura, Kazuya
Nakamae, Mika http://orcid.org/0000-0002-9200-4804
Okamura, Hiroshi
Sakatoku, Kazuki
Ido, Kentaro
Makuuchi, Yosuke
Kuno, Masatomo
Takakuwa, Teruhito
Hirose, Asao
Nishimoto, Mitsutaka
Nakashima, Yasuhiro
Koh, Hideo
Igarashi, Koji
Kubota, Hiroshi
Hino, Masayuki
Nakamae, Hirohisa
Funding for this research was provided by:
Tosoh (Tosoh)
Article History
Received: 14 September 2023
Accepted: 25 February 2024
First Online: 18 March 2024
Declarations
:
: This study was approved by the Ethics Committee of Osaka City University (the predecessor of Osaka Metropolitan University) Graduate School of Medicine (Approval no. 2020 − 213). This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
: According to our ethical guidelines and our institutional ethical committee, consent was obtained using an opt-out approach, where we provided information about the research framework and allowed participants to decline participation, rather than obtaining informed consent.
: All authors’ potential conflicts of interest in this research area are listed below. Except for Tosoh Corp., no direct funding was received for this research. No assistance with medical writing or data analysis work was received from the following companies. A patent application is pending for the results of this research from our university and Tosoh Cooperation. KT, KS, K Ido, AH and H Kubota have no conflicts of interests in this research area; M Nakamae: research funding from Veritas Corp. and honoraria to spouse (Please refer to HN disclosure); HO: research funding from Takeda Pharmaceutical Co., Ltd., and honoraria from Nippon Shinyaku Co., Ltd. and Asahi Kasei Pharma Corp.; YM: honoraria from Asahi Kasei Pharma Corp.; TT: research funding from Pfizer Japan Inc., Janssen Pharmaceutical K.K., and honoraria from Kyowa Kirin Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K. and Janssen Pharmaceutical K.K.; YN: research funding from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and honoraria from Novartis Pharma K.K., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd.; H Koh: research funding from Takeda Pharmaceutical Co., Ltd., and honoraria from Asahi Kasei Pharma Corp. and Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Nippon Shinyaku Co., Ltd., and Sumitomo Pharma Co., Ltd.; M.Nishimoto: research funding from Pfizer Japan Inc., and honoraria from Asahi Kasei Pharma Corp., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., and Janssen Pharmaceutical K.K.; K Igarashi: Employees of Tosoh Corportion,; MH: research funding from Tosoh Corp., Pfizer Japan Inc., Nippon Shinyaku Co., Ltd., Sekisui Medical Co., Ltd., ARKRAY, Inc. and donation for research from JCR Pharmaceuticals Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., Sumitomo Pharma Co., Ltd., and Sekisui Medical Co., Ltd., and honoraria from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Daiichi Sankyo Co., Ltd., Sumitomo Pharma Co., Ltd.; HN: research funding Novartis Pharma K.K., and Takeda Pharmaceutical Co., Ltd., and honoraria from Astellas Pharma Inc, Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma, and Janssen Pharmaceutical K.K.